WWW.NYTIMES.COM
23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million
Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.
0 Kommentare 0 Geteilt 90 Ansichten 0 Bewertungen